Genevention develops data integration platform and machine learning tools for prediction of undernutrition and treatment outcome assessment in elderly people: AMBROSIA

In older people with heart failure and atrial fibrillation, undernutrition is one of the key factors leading to inflammation, loss of function, disability and, ultimately, death. Since the inflammation is closely related to the intestinal microbiome, shaping the gut microbiota composition with a probiotic-based food could be an efficacious and safe approach to improve the cognitive functioning and skeletal muscle mass. AMBROSIA (Microbiota-Inflammation-Brain axis in heart failure: new food, biomarkerS and AI Approach for the prevention of undeRnutrition in Older) aims to develop an innovative food product to prevent undernutrition in HF and AF patients: a new chocolate bar containing a specific mix of probiotic strains and a cocktail of micro/macronutrients. The efficacy of the AMBROSIA bar on undernutrition prevention and its impact on cognitive functioning and skeletal muscle mass of older HF and AF patients will be evaluated through a prospective monocentric interventional clinical study. Several experimental high-throughput datasets such as biomarker, lipidomics and metagenomics profiles from urine, blood and saliva samples will be generated and analyzed during the AMBROSIA study. Using these data, statistical and machine learning methods will be developed for the identification of features from the “Microbiota-Inflammation-Brain axis” that are predictive for undernutrition (biomarkers) and/or related to AMBROSIA bar treatment outcome.

The AMBROSIA network consists of an international consortium with academic and industrial partners from five European countries (Italy, Spain, UK, Ireland, Germany). As an AMBROSIA partner, Genevention will develop a semantic data integration platform and knowledgebase for FAIR management and rich, harmonized annotation of clinical and experimental high-throughput data. We will develop, evaluate and integrate machine learning methods for identification of features from the “Microbiota-Inflammation-Brain axis” that are predictive for undernutrition and could be used as biomarkers. Statistical and machine learning tools will be developed and integrated in the platform for analysis of patient parameters related to treatment with the AMBROSIA bar. This work is financially supported by the German Federal Ministry of Food and Agriculture (BMEL) through the Federal Office for Agriculture and Food (BLE), grant number 2820ERA20E, (Cofund ERA-NET “ERA-HDHL”).

Genevention develops systems medicine platform for bone regeneration implants

Musculoskeletal disease is the most common cause of disability and loss of independency in the ageing populations across the globe. In this context, bone fractures and their complete healing also plays an important role. Due to the intrinsic regenerative capability of bone, in many cases, fractures can heal in a fast and effective way. However, healing of 10-15% of fractures is impaired leading to non-unions (failure of fracture healing after 6 months). Treatment of non-unions for patients comorbid with metabolic abnormalities such as type 2 diabetes mellitus (T2DM) is particularly difficult, and remains an unresolved clinical challenge. Within SyMBoD - a consortium of five academic partners and Genevention, funded by the BMBF - specialists congregated aiming at the provision of optimized and individualized diagnosis and therapy options promoting endogenous regeneration in this field of unsolved clinical need by the development of an innovative system medicine-based digital technology towards a theranostic platform. Patients with non-union and type 2 diabetes mellitus (T2DM) will serve as a role model to achieve a holistic understanding of system interplay that would impede regeneration and lead to substantial morbidity. In the second phase of the project, patients with a lack of endogenous bone regeneration capability (diagnostics based on omics and imaging data) will be provided with personalised (3D printed) smart implants that restore the hampered blood supply enabling cellular self-organization to regenerate defects that do not heal otherwise. Genevention will develop a digital platform for omics data management and 3D implant optimization based on semantic data integration technologies, analysis plugins for modeling and simulation and intuitive interfaces for clinical use cases.

  • «
  • 1 (current)
  • 2
  • »